在囊性纤维化中探索降低肺恶化率:流行病还是调节效应?
Anne L Stephenson1, Jenna Sykes1, Sanja Stanojevic2
1Division of Respirology, St Michael's Hospital, University of Toronto, ON, Canada.
ERJ open research
|October 29, 2025
概括
三重疗法elexacaftor-tezacaftor-ivacaftor (ETI) 在囊性纤维化 (CF) 患者中显著降低了肺恶化 (PEx). 欧洲资本贸易协会 (ETI)
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 估计elexacaftor-tezacaftor-ivacaftor (ETI) 对囊性纤维化 (CF) 肺部恶化 (PEx) 的影响是具有挑战性的,因为它是在COVID-19大流行期间引入的.
- 加拿大的ETI延迟访问提供了一个独特的机会,将其影响与与流行病有关的影响隔离到PEx率上.
研究的目的:
- 为了比较美国在ETI实施前和之后的PEx率.
- 使用加拿大PEx数据作为对照,以调整COVID-19大流行病的混乱影响.
主要方法:
- 使用美国和加拿大CF患者登记数据 (2015-2022) 的回顾性队列研究.
- 纳入标准:至少有一个F508del突变,年龄≥12岁.
- 统计分析涉及波桑回归和差异差异方法来估计ETI的孤立效应.
主要成果:
- 分析了22590名美国人和3271名加拿大人的数据.
- 流行前的PEx率在美国 (70.6) 高于加拿大 (53.1).
- 在大流行期间,PEx率在两个国家都下降了 (加拿大:30.2,美国:14.7).
- 经过调整后的分析显示,ETI对降低PEx的影响是疫情影响的2.48倍.
结论:
- 疫情期间的公共卫生措施在美国和加拿大减少了PEx.
- ETI对PEx减轻的治疗影响大大大大大大于与大流行相关的公共卫生干预措施的影响.
- ETI在缓解CF患者肺部恶化方面表现出显著且强大的效果.
相关概念视频
Cystic Fibrosis: Management
465
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
465
COPD: Management Using Bronchodilators and Corticosteroids
719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Chronic Obstructive Pulmonary Disease-I: Introduction
3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K


